Phathom Pharmaceuticals Valuation Multiples

Phathom Pharmaceuticals Overview

About Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Founded

2018

HQ

Employees

427

Website

phathompharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $209M

EBITDA: ($107M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Phathom Pharmaceuticals Financials

Phathom Pharmaceuticals reported last 12-month revenue of $209M and negative EBITDA of ($107M).

In the same LTM period, Phathom Pharmaceuticals generated $178M in gross profit, ($107M) in EBITDA losses, and had net loss of ($184M).

Phathom Pharmaceuticals P&L

In the most recent fiscal year, Phathom Pharmaceuticals reported revenue of $175M and EBITDA of ($145M).

Phathom Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals has current market cap of $980M, and enterprise value of $1B.

Phathom Pharmaceuticals' stock price is $12.56.

Phathom Pharmaceuticals Valuation Multiples

Phathom Pharmaceuticals trades at 5.0x EV/Revenue multiple, and (9.9x) EV/EBITDA.

Phathom Pharmaceuticals Financial Valuation Multiples

As of March 21, 2026, Phathom Pharmaceuticals has market cap of $980M and EV of $1B.

Equity research analysts estimate Phathom Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Phathom Pharmaceuticals has a P/E ratio of (5.3x).

Phathom Pharmaceuticals Margins & Growth Rates

Phathom Pharmaceuticals' revenue in the last 12 month grew by 79%.

Phathom Pharmaceuticals' revenue per employee in the last FY averaged $0.5M.

Phathom Pharmaceuticals' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Phathom Pharmaceuticals' rule of X is 147% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Phathom Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Phathom Pharmaceuticals M&A Activity

Phathom Pharmaceuticals acquired XXX companies to date.

Last acquisition by Phathom Pharmaceuticals was on XXXXXXXX, XXXXX. Phathom Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Phathom Pharmaceuticals Investment Activity

Phathom Pharmaceuticals invested in XXX companies to date.

Phathom Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Phathom Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).